The present disclosure provides ACE2-Fc fusion proteins comprising an ACE2 extracellular domain or fragment thereof and one or more Fc domains and methods of use thereof.

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

Compositions and methods are presented for prevention and/or treatment of a coronavirus disease wherein the composition comprises a recombinant entity. The recombinant entity comprises a nucleic acid that encodes a nucleocapsid protein of coronavirus 2 (CoV2); and/or wherein the recombinant entity encodes a spike protein of CoV2.

This invention provides a tetrahedral antibody comprising a first, second, third, and fourth domain, wherein: a) each of the first and second domains are selected from the group consisting of a Fab domain and an Fc domain, b) each of the first and second domains comprise: i) a first polypeptide chain comprising a first N-terminus of the domain, and ii) a second polypeptide chain comprising a second N-terminus of the domain, c) the first N-terminus of the first domain and the first N-terminus of the second domain are joined to each other by a non-peptidyl linkage wherein the non-peptidyl linkage is: i) a covalent linkage, or ii) a non-covalent linkage between (1) a first dimerizing polypeptide attached by a peptide bond or via a peptide linker to the first N-terminus of the first domain, and (2) a second dimerizing polypeptide attached by a peptide bond or via a peptide linker to the first N-terminus of the second domain, wherein the first and second dimerizing polypeptides are not immunoglobulin polypeptides, d) the third domain is attached at its C-terminus by a peptide bond or via a peptide linker to: i) the second N-terminus of the first domain, or ii) the N-terminus of the first dimerizing polypeptide, and e) the fourth domain is attached at its C-terminus by a peptide bond or via a peptide linker to: i) the second N-terminus of the second domain, or ii) the N-terminus of the second dimerizing polypeptide.

Methods and compositions relating to an engineered peptide capable of binding to an infectious biological molecule for inhibition by mediated degradation using the ubiquitin proteasome pathway. The engineered peptide includes a targeting domain and an ubiquitin ligase recruiting domain. The engineered peptide includes a targeting domain and an ubiquitin ligase. The targeting domain is computationally-derived from a known receptor for the infectious biological molecule. The engineered peptide is optimized for minimal size and minimum off-target effects.

The present invention relates to fusion proteins of ACE2 with IgG Fc and the medical use of these fusion proteins, in particular in the prevention or treatment of infections with coronaviruses such as SARS-CoV-2.

Disclosed herein are methods for inducing immunity against a severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV2) in a patient in need thereof. The method comprises administering a vaccine composition comprising a self-adjuvanted SARS-CoV2 Spike (S) RNA-based vaccine (AAHI-SC2), followed by administering a replication defective adenovirus (hAd5) vaccine composition, wherein the adenovirus comprises an E1 gene region deletion and an E2b gene region deletion.

A stabilized Ace2 variant has a disulfide bond introduced by substituting cysteine for amino acid residue pairs at specific positions of the Ace2 protein, thereby having excellent stability. The stabilized Ace2 variant exhibits high binding affinity for SARS-CoV-2 virus and excellent stability even in an aqueous solution condition. When the stabilized Ace2 variant is applied to a therapeutic agent for COVID-19, which is the SARS-CoV-2 infectious disease, the shelf stability, in-vivo stability, and therapeutic effect of the therapeutic agent may all be improved. In addition, since it uses the amino acid sequence derived from the receptor for SARS-CoV-2, it may effectively work even against various virus mutant strains.

The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

The present disclosure relates to recombinant fusion proteins comprising an extracellular domain of the human angiotensin-converting enzyme 2 (ACE2), optionally having altered amino acid residues that result in increased binding affinity for the S1 spike protein of SARS-CoV-2, linked to a human immunoglobulin Fc region, that can extend the protein half-life (T.sub.1/2) and/or the duration of action as a decoy receptor, and compositions and methods of use of these fusion proteins.